Amanote Research
Register
Sign In
An Amino-Acid Switch in the BCR-ABL Kinase Domain Modifies Sensitivity to Imatinib Mesylate
Leukemia
- United Kingdom
doi 10.1038/sj.leu.2403831
Full Text
Open PDF
Abstract
Available in
full text
Categories
Cancer Research
Oncology
Anesthesiology
Pain Medicine
Hematology
Date
June 23, 2005
Authors
T Leguay
V Desplat
V Lagarde
G Marit
J Reiffers
F-X Mahon
Publisher
Springer Science and Business Media LLC
Related search
Contribution of BCR-ABL Kinase Domain Mutations to Imatinib Mesylate Resistance in Philadelphia Chromosome Positive Malaysian Chronic Myeloid Leukemia Patients
Hematology Reports
Hematology
Imatinib Mesylate Resistance Through BCR-ABL Independence in Chronic Myelogenous Leukemia
Cancer Research
Cancer Research
Oncology
Kinase Domain Mutants of BCR-Abl Exhibit Altered Transformation Potency, Kinase Activity, and Substrate Utilization, Irrespective of Sensitivity to Imatinib
Molecular and Cellular Biology
Cell Biology
Molecular Biology
Kinase Domain Mutants of BCR Enhance BCR-Abl Oncogenic Effects
Oncogene
Cancer Research
Genetics
Molecular Biology
NPB001-05 Inhibits BCR-Abl Kinase Leading to Apoptosis of Imatinib-Resistant Cells
Frontiers in Bioscience - Elite
Immunology
Molecular Biology
Biochemistry
Microbiology
Medicine
Genetics
BCR-ABL Tyrosine Kinase
Science-Business eXchange
Imatinib Mesylate Induces Cisplatin Hypersensitivity in BCR-Abl+ Cells by Differential Modulation of P53 Transcriptional and Proapoptotic Activity
Cancer Research
Cancer Research
Oncology
Prognostic Significance of Micro RNA 150 Marker in BCR-ABL Positive Chronic Myeloid Leukaemia Patients on Imatinib Mesylate
International Journal of Contemporary Pediatrics
Simultaneous Targeting of Aurora Kinases and BCR-Abl Kinase by the Small Molecule Inhibitor PHA-739358 Is Effective Against Imatinib-Resistant BCR-ABL Mutations Including T315I
Blood
Biochemistry
Immunology
Cell Biology
Hematology
